202 related articles for article (PubMed ID: 29188727)
1. The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?
Aoun F; El Rassy E; Sleilaty G; Assi T; Bakouny Z; Kattan J
Future Oncol; 2017 Dec; 13(30):2785-2790. PubMed ID: 29188727
[TBL] [Abstract][Full Text] [Related]
2. Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone.
Jones RJ
Oncology (Williston Park); 2018 May; 32(5):223, 226-7, 247. PubMed ID: 29847852
[No Abstract] [Full Text] [Related]
3. Point: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Chemotherapy.
Isaacsson Velho P; Eisenberger MA
Oncology (Williston Park); 2018 May; 32(5):223-6. PubMed ID: 29847851
[No Abstract] [Full Text] [Related]
4. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
Caffo O; Veccia A; Kinspergher S; Maines F
Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study.
Suzuki H; Shin T; Fukasawa S; Hashine K; Kitani S; Ohtake N; Shibayama K; Tran N; Mundle S; Fizazi K; Matsubara N
Jpn J Clin Oncol; 2020 Jul; 50(7):810-820. PubMed ID: 32188988
[TBL] [Abstract][Full Text] [Related]
6. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
[TBL] [Abstract][Full Text] [Related]
7. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
Scott LJ
Drugs; 2017 Sep; 77(14):1565-1576. PubMed ID: 28819727
[TBL] [Abstract][Full Text] [Related]
10. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
[TBL] [Abstract][Full Text] [Related]
12. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Vale CL; Fisher DJ; White IR; Carpenter JR; Burdett S; Clarke NW; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Rydzewska LH; Sweeney CJ; Spears MR; Sydes MR; Tierney JF
Ann Oncol; 2018 May; 29(5):1249-1257. PubMed ID: 29788164
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
Kassem L; Shohdy KS; Abdel-Rahman O
Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
[TBL] [Abstract][Full Text] [Related]
14. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
Petrioli R; Francini E; Laera L; Fiaschi AI; Ponchietti R; Roviello G
Cancer Chemother Pharmacol; 2015 Sep; 76(3):439-45. PubMed ID: 26082421
[TBL] [Abstract][Full Text] [Related]
15. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
Boissier E; Loriot Y; Vignot S; Massard C
Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
[TBL] [Abstract][Full Text] [Related]
16. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
[TBL] [Abstract][Full Text] [Related]
17. Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.
Okamoto T; Noro D; Hatakeyama S; Narita S; Mitsuzuka K; Sakurai T; Kawamura S; Hoshi S; Shimoda J; Tanaka T; Kawaguchi T; Ishidoya S; Ito A; Tsuchiya N; Habuchi T; Ohyama C
BMC Cancer; 2021 May; 21(1):605. PubMed ID: 34034691
[TBL] [Abstract][Full Text] [Related]
18. [Maximal androgen deprivation with abiraterone acetate in hormone sensitive prostate cancer.].
Rodríguez Antolín A; Romero Otero J; Duarte Ojeda J; García González L; Sopeña Sutil R; González Padilla D; García Rojo E; Justo Quintas J; Miñana López B
Arch Esp Urol; 2018 Mar; 71(3):267-275. PubMed ID: 29633947
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
Elkon JM; Millett RL; Millado KF; Lin J
Expert Opin Pharmacother; 2018 Apr; 19(5):507-509. PubMed ID: 29494266
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate in the treatment of prostate cancer.
Thakur A; Roy A; Ghosh A; Chhabra M; Banerjee S
Biomed Pharmacother; 2018 May; 101():211-218. PubMed ID: 29494958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
